Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer

This publication has 17 references indexed in Scilit:

• 65 Weekly paclitaxel — Marked activity, diminished toxicity and platelet stimulating effect
  Lung Cancer, 1997
• 1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)
  European Journal Of Cancer, 1995
• Paclitaxel (Taxol)
  New England Journal of Medicine, 1995
• Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
  Cancer, 1995
• Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1993
• Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results
  JNCI Journal of the National Cancer Institute, 1993
• Mechanism of action of taxol
  Trends in Pharmacological Sciences, 1992
• Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a Day 1 and Day 8 High-Dose Regimen
  JNCI Journal of the National Cancer Institute, 1989
• Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer
  American Journal of Clinical Oncology, 1988
• New platinum complexes in clinical trials
  Cancer Treatment Reviews, 1983